Health-related quality of life in patients with locally advanced or metastatic breast cancer treated with eribulin mesylate or capecitabine in an open-label randomized phase 3 trial
Crossref DOI link: https://doi.org/10.1007/s10549-015-3633-7
Published Online: 2015-11-14
Published Print: 2015-12
Update policy: https://doi.org/10.1007/springer_crossmark_policy
Cortes, Javier
Hudgens, Stacie
Twelves, Chris
Perez, Edith A.
Awada, Ahmad
Yelle, Louise
McCutcheon, Susan
Kaufman, Peter A.
Forsythe, Anna
Velikova, Galina
License valid from 2015-11-14